Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2014 Fourth Quarter Earnings
April 01 2014 - 8:00AM
Business Wire
Forest Laboratories, Inc. (NYSE:FRX), a leading fully
integrated, specialty pharmaceutical company largely focused on the
United States market, will release its Fiscal 2014 Fourth Quarter
financial results before the U.S. stock market opens on Tuesday,
April 29, 2014. At 10:00 AM EDT, Forest will host a conference call
to discuss the financial results and relevant company and industry
topics.
The conference call will be webcast live beginning at 10:00 AM
EDT on the Company's website www.FRX.com. Please log on to the
website at least fifteen minutes prior to the conference call as it
may be necessary to download software to access the call. A replay
of the conference call will be available until May 28, 2014 at both
websites and also by dialing (800) 283-7928 (US and Canada) or
(402) 220-0866 (international), Conference Call ID # FRXQ414.
About Forest Laboratories and Its
Products
Forest Laboratories (NYSE: FRX) is a leading, fully integrated,
specialty pharmaceutical company largely focused on the United
States market. The Company markets a portfolio of branded drug
products and develops new medicines to treat patients suffering
from diseases principally in five therapeutic areas: central
nervous system, cardiovascular, gastrointestinal, respiratory,
anti-infective and cystic fibrosis. Our strategy of acquiring
product rights for development and commercialization through
licensing, collaborative partnerships and targeted mergers and
acquisitions allows us to take advantage of attractive late-stage
development and commercial opportunities, thereby managing the
risks inherent in drug development. The Company is headquartered in
New York, NY. To learn more, visit www.FRX.com.
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve a number of risks and uncertainties,
including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to
time in Forest Laboratories’ Annual Report on Form 10-K, Quarterly
Reports on Form 10-Q and any subsequent SEC filings. Forest assumes
no obligation to update forward-looking statements contained in
this release to reflect new information or future events or
developments.
Forest Laboratories, Inc.Frank J. MurdoloVice President -
Investor Relations,1-212-224-6713investor.relations@frx.comorAmanda
KaufmanSenior Manager Corporate Communications and Media
Relations,amanda.kaufman@frx.com
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024